Accelerate Diagnostics to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 16, 2022, at 10:00 a.m. Eastern Time

Rhea-AI Summary

Accelerate Diagnostics, Inc. (NASDAQ: AXDX) will present virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 16, 2022, at 10:00 a.m. ET. The conference is exclusive to BTIG clients. Accelerate Diagnostics focuses on in vitro diagnostics, addressing antibiotic resistance and sepsis challenges. Their FDA-cleared Accelerate Pheno® system provides rapid phenotypic antibiotic susceptibility results in approximately 7 hours, enabling timely and optimal antibiotic therapy for patients, significantly faster than traditional methods.

TUCSON, Ariz., Feb. 2, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that the company is scheduled to present virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 16, 2022, at 10:00 a.m. Eastern Time.

BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative with interest

About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Pheno^® system and Accelerate PhenoTest^® BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the most optimal antibiotic therapy for deadly infections. The FDA cleared system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results in approximately 7 hours direct from positive blood cultures. Recent external studies indicate the solution offers results 1-2 days faster than existing methods, enabling clinicians to optimize antibiotic selection and dosage specific to the individual patient days earlier.

The "ACCELERATE DIAGNOSTICS" and "ACCELERATE PHENO" and "ACCELERATE PHENOTEST" and diamond shaped logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc.

For more information about the company, its products and technology, or recent publications, visit axdx.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/accelerate-diagnostics-to-participate-in-btig-medtech-digital-health-life-science--diagnostic-tools-conference-on-february-16-2022-at-1000-am-eastern-time-301473773.html

SOURCE Accelerate Diagnostics, Inc.

FAQ

When is Accelerate Diagnostics presenting at the BTIG conference?

Accelerate Diagnostics will present on February 16, 2022, at 10:00 a.m. Eastern Time.

What is the focus of Accelerate Diagnostics?

Accelerate Diagnostics specializes in in vitro diagnostics for antibiotic resistance and sepsis.

What technology does Accelerate Diagnostics use?

The company uses the Accelerate Pheno® system to provide rapid antibiotic susceptibility results.

How long does it take for Accelerate Diagnostics to report results?

The Accelerate Pheno® system reports results in approximately 7 hours.

What advantages does the Accelerate Pheno® system offer?

It provides results 1-2 days faster than existing methods, enabling quicker clinical decision-making.